Status:
UNKNOWN
Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
Ministry of Science and Technology, Taiwan
Conditions:
Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Steatohepatitis
Eligibility:
All Genders
20+ years
Brief Summary
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Non-alcoholic steatohepatitis (NASH) is an aggressive form of NAFLD with remarkable inflammatory features which may ...
Detailed Description
The investigators anticipate to recruit 140 morbidly obese patients who will receive bariatric surgery including 100 patients receiving sleeve gastrectomy (SG) and 40 receiving gastric bypass surgery ...
Eligibility Criteria
Inclusion
- Age \>20，morbidly obese patients who will receive bariatric surgery.
Exclusion
- Average daily alcohol intake \>20 grams,
- Hepatitis B carriers, Hepatitis C carriers,
- people with liver disease caused by other causes
- liver cirrhosis,
- diseases related to abnormal blood coagulation,
- inflammatory bowel disease,
- routine use of steroids or immunity Inhibitors and other immunomodulatory drugs
- ursodeoxycholic and other drugs that affect bile acid metabolism
- those who have used antibiotics or probiotics within one month
Key Trial Info
Start Date :
May 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04501042
Start Date
May 16 2019
End Date
September 1 2024
Last Update
September 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100